Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

SEC Filing Details

Document Details

Form
Filing Date
February 3, 2022
Document Date
February 1, 2022
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Tarsus Pharmaceuticals
Issuer
TARSUS PHARMACEUTICALS, INC.